Clinical Trials Logo

Cognitive Deficits clinical trials

View clinical trials related to Cognitive Deficits.

Filter by:

NCT ID: NCT04064021 Withdrawn - Alzheimer Disease Clinical Trials

Acupuncture Treatment for Improving Alzheimer's Dementia

Start date: January 1, 2025
Phase: N/A
Study type: Interventional

Evaluate cognitive improvement pre amd post acupuncture treatment in patients with probable alzheimer's dementia as measured by MOCA score and also per form A( measure of patient's personal information). Also caregiver input.

NCT ID: NCT03623477 Completed - Schizophrenia Clinical Trials

Can Cognitive Training Decrease Reactive Aggression?

Start date: August 16, 2016
Phase: N/A
Study type: Interventional

The purpose of the study is to examine the effects of cognitive training on emotion regulation, impulse control, and aggression in people with schizophrenia. The study compares a combination of computerized cognitive remediation and social cognition training (CRT+SCT) to cognitive remediation alone (CRT). Study outcomes include multiple measures of aggression, emotion regulation, impulse control, cognition, and symptoms.

NCT ID: NCT03621540 Completed - Schizophrenia Clinical Trials

Augmentation of Working Memory Training With Transcranial Direct Current Stimulation in Patients With Schizophrenia

Start date: April 20, 2018
Phase: N/A
Study type: Interventional

Cognitive impairment is a core symptom of schizophrenia and is in a large part responsible for the poor psychosocial outcome of the disorder. The use of non-invasive brain stimulation techniques as a therapeutic option is just commencing for neuropsychiatric patients. Concerning healthy subjects the investigators have previously shown that anodal tDCS to the right dorsolateral prefrontal cortex (DLPFC) parallel to working memory training can sustainingly enhance performance in a spatial n-back task. Additionally, first translational experiments regarding the use of anodal tDCS to improve working memory (WM) in patients with schizophrenia rendered promising results. On those grounds, the investigators now test the hypothesis that anodal tDCS to the right DLPFC can augment working memory training in patients with schizophrenia.

NCT ID: NCT03017560 Completed - Cognitive Deficits Clinical Trials

Treating Verbal Memory Deficits Following Chemotherapy for Breast Cancer

Start date: December 2015
Phase: N/A
Study type: Interventional

The primary purpose of this study is to test the effects of a targeted, computerized cognitive training program on verbal memory in older women who have undergone chemotherapy treatment for early-stage breast cancer. As measured by neuropsychological assessment, this treatment will result in improved verbal memory. Secondarily, processing speed and naming abilities are expected to improve. Enhanced self-perception of cognitive ability is also expected.

NCT ID: NCT02847793 Completed - Depression Clinical Trials

Attentional Bias Modification Through Eye-tracker Methodology (ABMET)

ABMET
Start date: April 1, 2016
Phase: N/A
Study type: Interventional

Cognitive biases are a hallmark of depression but there is scarce research on whether these biases can be directly modified by using specific cognitive training techniques. The aim of this study will be targeting and modifying specifically relevant attention biases in participants with subclinical depression using eye-tracking methodologies. This innovative approach has been proposed as a promising future line of intervention in Attention Bias Modification procedures (Koster & Hoorelbeke, 2015). Recent findings suggest that depression is characterized by a double attentional bias (Duque & Vazquez, 2015), More specifically, depressed individuals have difficulties both to disengage from negative materials (e.g., sad faces) and to engage with positive materials (e.g., happy faces). Thus, training procedures to change attentional biases should target these two separate components.

NCT ID: NCT02816008 Completed - Cognition Disorders Clinical Trials

Smart Autonomous Neuro-Rehabilitation System

SANaR
Start date: July 2016
Phase: N/A
Study type: Interventional

Cognitive rehabilitation is defined as a systematic functionally oriented intervention of therapeutic cognitive activities based on the assessment and understanding of patient's brain behavior deficits. This project focuses on restoring cognitive functions in order to understand the underlying deficits in the patient's brain by developing integrated cognitive rehabilitation scenarios in virtual reality that combine memory, attention and problem solving training with context specific motor movements.

NCT ID: NCT02746523 Terminated - Clinical trials for Proprioceptive Disorders

Effects of Multiple Concussions in Retired NHL Players

NHL
Start date: March 2016
Phase: N/A
Study type: Observational

To investigate long term affects of multiple concussions on the cognition, balance, proprioception, and biomarkers in retired National Hockey League players

NCT ID: NCT02505477 Completed - Schizophrenia Clinical Trials

Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine

NAC2
Start date: February 6, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to attempt to treat cognitive and negative symptoms of schizophrenia, with the nutritional supplement N-acetylcysteine (NAC). Schizophrenia is a chronic mental disorder that affects approximately 65 million people worldwide, and causes significant disability and suffering. Patients with schizophrenia often hear voices and have persecutory delusions. Though these are the most recognizable features of the illness, the deficits most closely linked to disability are known as cognitive deficits and negative symptoms. Cognitive abilities refer to the ability to perform mental tasks that require focus and attention, and also include memory and verbal skills. Negative symptoms refer to a lack of interest in the world, and decreased social interactions. In our study, the investigators aim to improve these symptoms and deficits by targeting the glutamate system. Glutamate is the major excitatory neurotransmitter in the brain, and its regulation is abnormal in schizophrenia: glutamate levels are too low at some receptors, and too high at others. As well, free radicals surrounding glutamate receptors also interfere with their proper function. N-acetylcystine (NAC) is a safe and widely-available dietary supplement that may restore glutamate to its correct levels in the brain, and may also help protect the brain from antioxidant damage. In our study, patients with schizophrenia will be randomly assigned to receive either NAC or placebo for 8 weeks. Brain levels of glutamate and an important antioxidant, glutathione, will be measured before and after treatment, using a neuroimaging technique known as magnetic resonance spectroscopy. Cognitive and negative symptoms will also be assessed before, during and after treatment. The investigators hypothesize that glutamate and glutathione will be normalized in patients' brains, and that their negative and cognitive symptoms will be improved, too.

NCT ID: NCT02393079 Completed - Brain Injury Clinical Trials

Analysis of TCLT in TBI Patients: a Prospective, Randomized Controlled Trial

Start date: January 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the early and late effects of Transcranial Led Therapy (TLTC) in memory and executive functions in patients with moderate and severe TBI history (TBI time longer than 3 months).

NCT ID: NCT02360813 Completed - Schizophrenia Clinical Trials

Cognitive Remediation Therapy Within a Secure Forensic Setting

Start date: August 2014
Phase: N/A
Study type: Interventional

This clinical trial tests the feasibility, effectiveness and patient satisfaction with cognitive remediation therapy for patients diagnosed with schizophrenia or schizoaffective disorder within a forensic hospital. It is hypothesised that patients receiving cognitive remediation therapy will have an improvement in cognitive performance, real world functioning, symptoms, violence risk and benefit more from additional psychosocial treatment programmes over time relative to patients receiving treatment as usual. Furthermore it is hypothesised that it will be feasible to carry out such a study and that patients will report high rates of satisfaction with cognitive remediation therapy. Finally it is hypothesised that differences on the effectiveness measures will be maintained at 6 month follow up after the end of treatment.